Pfizer to Present 45 Oncology Abstracts at ESMO 2026
NEW YORK — September 28, 2026 Pfizer Inc. announced that it will present data from 45 company-sponsored, investigator-sponsored and...
XTANDI
Advertisement
Galmed Reports Aramchol Data in Prostate Cancer Models
Ramat Gan, Israel, August 17, 2026 Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and oncology...
Pfizer Inc. Wins FDA Priority Review for Prostate Cancer Therapy
NEW YORK, July 22, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets
MUMBAI, India & NAPLES, Fla., June 26, 2026 Lupin Limited announced that it has received tentative approval from the...
Foundation Medicine Gains FDA Approval for TALZENNA CDx
BOSTON, June 1, 2026 Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved both FoundationOne®...
Advertisements
Pfizer TALZENNA XTANDI Boost Survival in Prostate Cancer
NEW YORK, March 19, 2026 Pfizer Inc. announced that its Phase 3 TALAPRO-3 clinical trial evaluating TALZENNA® (talazoparib) in...
Advertisement
